Application of ABCA1 and CD68 as prognosis markers in preparation of liver cancer prognosis prediction kit

Abstract

The invention discloses an application of ABCA1 and CD68 as prognosis markers in preparation of a liver cancer prognosis prediction kit. The research shows that the prognosis survival of a patient can be clinically and effectively predicted in an auxiliary manner by detecting the co-expression ratio of CD68 and ABCA1. The invention also provides a double-antibody combined fluorescence detection kit for prognosis prediction after liver cancer resection, which comprises a first antibody of the combination of ABCA1 and CD68 antibodies, a second antibody marked by horse radish peroxidase, and a tyramine signal amplification reagent. The kit can detect the expression proportion of macrophage ABCA1 in tissues by adopting a double-antibody combined tyramine signal amplification method, and has the characteristics of objectivity, accuracy and high efficiency. The kit is applied to detection of the expression mode of macrophages ABCA1 infiltrated in liver cancer tumor tissues, and can predict survival prognosis of patients.

Description

technical field [0001] The present invention relates to the technical field of disease prognosis diagnosis, in particular to the application of ABCA1 and CD68 as prognosis markers in the preparation of liver cancer prognosis prediction kits. Background technique [0002] Primary hepatocellular carcinoma (hereafter referred to as liver cancer) is one of the most common malignant tumors with the worst prognosis in my country, and its morbidity and mortality rank among the forefront of malignant tumors. At present, the most effective methods for the treatment of liver cancer are still surgical resection and liver transplantation; however, most patients are already in the middle and advanced stages when they are diagnosed, and do not have the conditions for surgery. lower. Therefore, effectively predicting the overall survival of patients after surgery will help to select the appropriate treatment population and methods, and provide strong support for effective diagnosis and tr...

AI Technical Summary

Problems solved by technology

However, the existing technology has the following disadvantages: (1) the above traditional clinicopathological diagnosis or a single molecular marker has low efficacy and poor accuracy in judging the prognosis of patients after surgery; (2) although a single myeloid cell marker can also To a certain extent, it can predict the prognosis of patients, but in fact it cannot fully reflect the actual situation of myeloid cell function in tumors

At present, there are few reports on the role of ABCA1 and CD68 in the prognosis and survival of patients with liver cancer

Images